Member Info for AgentB

WG what is it? A portrait of Joe Biden?

Another institutional investor is positive about bitcoin = another sign that the next break out will be up rather than down.
https://citywire.co.uk/funds-insider/news/ruffer-bitcoin-at-foothills-of-long-trend-of-institutional-adoption/a1451296?re=81607&ea=1503446&utm_source=BulkEmail_FundsInsider+DawnChorus&utm_medium=BulkEmail_FundsInsider+DawnChorus&utm_campaign=BulkEmail_FundsInsider+DawnChorus

"In terms of the smart Biotech which makes the test work itlooks like it’s down to Aptamers ( Aptamer group ) and Affimers ( Avacta group)
We believe both are at Porton Down and undergoing clinical review, more than likely only one of the two will be successful in securing the government contract
Based on what we know Avacta should outperform Aptamer Group but we don’t really know 100%
For me this raises a number of questions:
1) What makes us think that it's a binary choice? Is there any argument that using both in combination would be a 'belt and braces' and superior approach? (I'm no scientist, but I note that Deepverge uses both Affimers and Aptamers in its sewage monitoring - presumably for a reason.)
2) If we are convinced that it's one or the other, what are the reasons for thinking Affimers are likely to give superior performance within and LFT than Aptamers? Can anyone list the advantages of Affimers over Aptamers? I presume stability/replicability/ease of manufacture are important features, but is there one 'killer featire' that would make Affimers the obvious choice?
3) How many on here are hedging their bets with exposure to ODX and with what percentage in each (as an indicator of degree of confidence.)

Better ask Timster

Sorry, they “crossed in the post” ;-)

Note no mention of the fact ARB can be held in an ISA though (unless I missed it.)

https://www.dailymail.co.uk/money/investing/article-9148775/Why-Argo-Blockchain-popular-stock-2021-far.html

“With 0.5 on the BIS - ALL TRADES TAKE Vwap NORTH !!!!”

Ooh, I like days like this!

Goldman Sachs wanting in is not necessarily a good thing. This article (from 2010) accuses them of engineering every major market manipulation since the Great Depression.

“The bank’s unprecedented reach and power have enabled it to turn all of America into a giant pump-and-dump scam, manipulating whole economic sectors for years at a time, moving the dice game as this or that market collapses, and all the time gorging itself on the unseen costs that are breaking families everywhere”

https://www.rollingstone.com/politics/politics-news/the-great-american-bubble-machine-195229/

Here come the viles! (Being our new word for derampers.)

Interestingly the collaboration is for POC testing rather than Lateral Flow Tests. LFT is for Sona and Aptamer Group.

So what we could be looking at is a consortium produced nasal swab lft for Govt use (not part of tender) and an Avacta/Cytiva branded saliva based lft which could be in the tender if Avacta has lined up production elsewhere?

It’s also a subtle hint to shareholders frustrated with current delays as to the reasons behind them!

It’s been spotted in the last week or so.

The below is taken from revamped Avacta website. Seems that Affimer reagents have been validated in accordance with FDA/EMEA guidelines. Presumably should speed up ex U.K. approvals?
One thing that strikes me - as a non scientist - reading Avacta’s description of what it does in the diagnostic division is the sheer confidence expressed wrt the Affimer platform and its potential uses. They don’t name Covid specifically, they don’t need to because they are looking beyond it to whatever else may need to be diagnosed (and they are doing so with supreme confidence.)

Benefit of Affimer® immunoassays

* Excellent target specificity: Allows accurate and reproducible quantification of antigens of interest across multiple immunoassay platforms
* Highly sensitive target detection: Showing no matrix effect and no cross-reactivity with highly homologous proteins Affimer® reagents can be validated to regulatory standards over clinically relevant concentration ranges.
* Flexible formatting: Affimer® reagents can be easily modified with functional groups and tags to suit all assay requirements.
* Highly stable in a wide range of assay conditions: Exposure to a wide range of pH, temperature, organic solvents and long-term storage has no effect on Affimer® reagent assay performance.
* Rapid development: Our proven Affimer® binder process typically takes 12 weeks, helping you to meet tight product development timelines.
* Batch-to-batch reproducibility: Affimer® reagents have been validated in accordance with FDA/ EMEA regulatory guidelines for critical reagents.
https://avacta.com/diagnostics/affimer-applications/affimer-immunoassay-reagents/

US market reaction will probably be boosted by some supportive PR from our new agency. That’s why I said that I hoped they also had this side of the pond covered. A new video from PW explaining the thinking and the timing of this move would have helped.

There was actually quite a decent joke on here earlier. I copied and sent it to some friends. Can’t find it now though. :(

I have just defunded LSE. I asked them to cancel my premium membership until they can supply a service that’s worthy of the money. (Deja vu really cos I did the same with the BBC earlier in the year! ) ;-)

Yes but it didn’t appear on some media. I got this from LSE at 08:32:

Hi

Our technical team in contact with the supplier regarding the missing RNS releases and they should hopefully be on the website soon.

Kind regards
Claire

Soon as in tomorrow maybe? I hope this isn’t down to the new PR Agency!

Interesting!

Will January 29 become D-Day for Bitcoin?

As data from Deribit shows, 29 January could be a seminal day for Bitcoin in the coming weeks. 45% of all bitcoin options expire on 29 January. This is once again significantly more than the previous ATH of 25 December 2020, when there was the largest expiry of Bitcoin options to date, with a volume of $2.4 billion. However, according to the latest data from Deribit, there are 94,060 bitcoins on the expiry calendar for 29 January.

This large volume shows that there is an unusually high concentration that could have a strong impact on the BTC price. However, the positive news is that the data is bullish. For example, there are quite a few call options at the $46,000 level and only a few put options below $28,000. However, these are considered worthless as they are outside the current price trend.

Matt Han**** on at 17:00 hrs.
Can’t be Moonshot, as Boris must surely want the glory of that announcement!